Recognizing Tysabri-Related PML Symptoms

Latest update (2026-07)

Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]

Legacy of Vigilance in Medical Monitoring

If you or a loved one is taking Tysabri, understanding the early signs of progressive multifocal leukoencephalopathy (PML) is critical. The history of post-market surveillance has shown that timely recognition of symptoms can influence outcomes. This page outlines the key symptoms to watch for, based on research and product labeling.

Medical Evidence and Risk Factors for Tysabri-Associated PML

Tysabri (natalizumab) is a monoclonal antibody indicated as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. The United States Food and Drug Administration (FDA) has mandated a boxed warning on the Tysabri label, stating that the drug "increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain that usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This warning is central to understanding both the clinical risks and the legal landscape for affected patients, particularly regarding settlement considerations and the statute of limitations in New Jersey. The clinical presentation of PML is variable but typically involves subacute neurological deficits such as cognitive decline, motor weakness, visual disturbances, or speech difficulties. Diagnosis relies on brain MRI showing characteristic white matter lesions and detection of JC virus DNA in cerebrospinal fluid via polymerase chain reaction. The Tysabri label identifies three key risk factors for PML: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy, as the expected benefit must be weighed against the risk of PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Mechanistically, Tysabri works by binding to alpha-4 integrins on leukocytes, preventing their migration across the blood-brain barrier. This reduces inflammation in the central nervous system but also impairs immune surveillance, allowing latent JC virus to reactivate and cause PML. The drug's immunosuppressive effect is dose- and duration-dependent, which explains why longer exposure increases risk. The label explicitly notes that PML "typically only occurs in patients who are immunocompromised" and that Tysabri treatment creates this vulnerability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).

Adequacy of Warnings and Regulatory Oversight

Regarding the adequacy of warnings, the FDA has required a boxed warning since Tysabri was reintroduced to the market in 2006 after a temporary withdrawal. The label instructs healthcare professionals to "monitor patients on TYSABRI for any new sign or symptom that may be suggestive of PML" and to "withhold TYSABRI immediately at the first sign or symptom suggestive of PML" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Additionally, Tysabri is only available through a restricted distribution program called the TOUCH Prescribing Program, which requires patient enrollment and education about PML risks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, some patients have developed PML, leading to litigation and settlement programs. For patients in New Jersey considering legal action related to Tysabri-associated PML, the statute of limitations is a critical factor. In New Jersey, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. This "discovery rule" means the clock starts when the patient knew or should have known that Tysabri caused their PML. Given that PML symptoms can develop insidiously over weeks to months, the timeline between exposure and documented harm is variable. The label notes that PML has occurred in patients treated for various durations, and the risk increases with longer therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Therefore, the date of diagnosis—confirmed by MRI and JC virus testing—typically triggers the statute of limitations.

Settlement Considerations and Legal Recourse

Settlement-related considerations for affected patients often involve evaluating the strength of the claim based on the adequacy of warnings and the presence of risk factors. The boxed warning clearly states the risk, but plaintiffs may argue that their healthcare provider did not adequately communicate this risk or that the TOUCH program failed to prevent harm. Settlement amounts may account for medical expenses, lost income, pain and suffering, and the severity of disability. Because PML "usually leads to death or severe disability" (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962), claims often involve catastrophic injuries. In summary, the medical evidence establishes a clear causal link between Tysabri and PML, with well-defined risk factors and mandated warnings. For New Jersey patients, the statute of limitations is typically two years from discovery of the injury, and settlement considerations hinge on the adequacy of risk communication and the severity of harm. Legal counsel should be sought promptly to preserve claims.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Tysabri PML claims in New Jersey?

In New Jersey, personal injury claims generally must be filed within two years from the date the injury was discovered or reasonably should have been discovered. This 'discovery rule' means the clock starts when the patient knew or should have known that Tysabri caused their PML. The date of diagnosis, confirmed by MRI and JC virus testing, typically triggers the statute of limitations.

What are the key risk factors for developing PML from Tysabri?

The Tysabri label identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing therapy.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Tysabri exposure and a confirmed Progressive Multifocal Leukoencephalopathy diagnosis may request an independent eligibility review. [Begin Assessment]

References

FDA DailyMed Tysabri Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.